^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Ameile (aumolertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

    Excerpt:
    ...Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R)....
    Trial ID:
    ATTRACT
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

    Excerpt:
    ...5) The tumour harbours one of the EGFR mutations (Ex19del, L858R, G719AG719CG719SL861Q). ...
    Trial ID:
    ChiCTR2000035591
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2022
    Title:

    EP08.02-050 - A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

    Published date:
    07/12/2022
    Excerpt:
    We included 5 patients with EGFRm NSCLC and LM at Nanjing Chest Hospital, whose median age was 54 years, predominantly female (80%). EGFR mutations included exon 21 L858R mutation, T790M mutation, exon 19 deletion combined with TP53 mutation, and c-MET amplification....Aumolertinib in combination with bevacizumab has shown significant efficacy in patients with LM NSCLC with exon 19 deletion and exon 21 L858R mutations, even in combination with non-sensitive mutations and poor physical status.